Certara's Better Drug Discovery and Development Process
The drug discovery and development process is long and expensive with more failures than successes. At Certara, we anticipate and address your critical drug discovery and development risks and decisions using biosimulation, technology and services.
In 2021, more than 2,000 customers worldwide chose Certara as their trusted partner for our gold-standard biosimulation software and technology-driven services. We support confident decision-making throughout the entire biopharma R&D process to reduce cycle times, lower costs and improve outcomes for patients.
Additionally, 17 global regulatory agencies have adopted our Phoenix™ PK/PD, Pinnacle 21 and/or Simcyp™ PBPK Simulator software, including the US FDA, Japan's PMDA and China's NMPA.
We are proud to say that our customers, who use our biosimulation software and services, have received 90% of all new drug approvals by the FDA since 2014.
How we help our clients
Latest from Certara
How will Project Optimus impact your program?
Optimus Fitness & Gap Analysis Solutions
Drug interactions with therapeutic proteins, regulatory expectations and modeling and simulation approaches
Attn: Data Managers
Pinnacle 21 Data Exchange Module
Leveraging Clinical Data from One Rare Disease to Support Drug Approval for Another
Try 30 days of Market Access Radar
The Growing Value of QSP
Certara Acquires Vyasa, an Artificial Intelligence Company that Delivers Predictions to Accelerate Scientific Innovation
Join our team
- Collaborate with leading experts
- Work on a wide range of drug programs
- Enjoy flexibility, competitive benefits, and a culture of passion and fun